Dengue Fever – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Dengue Fever Market Outlook

Thelansis’s “Dengue Fever Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dengue Fever treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dengue Fever Overview

Dengue virus infection is the most widespread arthropod-borne viral illness in humans. It is primarily transmitted by Aedes mosquitoes, including A. aegypti and A. albopictus, which become infected by biting a person with the virus in their bloodstream. Dengue fever typically becomes symptomatic after an incubation period of 4-10 days, with symptoms lasting 2-7 days. Many patients with dengue may not exhibit any symptoms, while others may experience chills, rash, erythematous mottling of the skin, and facial flushing for 2-3 days. Severe dengue fever occurs in less than 5% of cases, with most fatalities occurring in children and adolescents. Severe dengue, also known as Dengue hemorrhagic fever or Dengue shock syndrome, is characterized by increased vascular permeability, leading to hypovolemic shock and death. The Dengue virus has four serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). The disease can progress to severe dengue fever, leading to damaged blood vessels and fluid leakage, decreased platelet count causing severe bleeding, sudden blood pressure drops, and systemic failure that may culminate in death.

• The global incidence of dengue has grown dramatically, with about half of the world's population at risk. Although an estimated 100-400 million infections occur yearly, over 80% are generally mild and asymptomatic.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: